293 related articles for article (PubMed ID: 16847290)
1. Effects of sibutramine treatment in obese adolescents: a randomized trial.
Berkowitz RI; Fujioka K; Daniels SR; Hoppin AG; Owen S; Perry AC; Sothern MS; Renz CL; Pirner MA; Walch JK; Jasinsky O; Hewkin AC; Blakesley VA;
Ann Intern Med; 2006 Jul; 145(2):81-90. PubMed ID: 16847290
[TBL] [Abstract][Full Text] [Related]
2. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.
Berkowitz RI; Wadden TA; Tershakovec AM; Cronquist JL
JAMA; 2003 Apr; 289(14):1805-12. PubMed ID: 12684359
[TBL] [Abstract][Full Text] [Related]
3. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study.
Daniels SR; Long B; Crow S; Styne D; Sothern M; Vargas-Rodriguez I; Harris L; Walch J; Jasinsky O; Cwik K; Hewkin A; Blakesley V;
Pediatrics; 2007 Jul; 120(1):e147-57. PubMed ID: 17576783
[TBL] [Abstract][Full Text] [Related]
6. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
7. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
9. Long-term weight loss with sibutramine: a randomized controlled trial.
Wirth A; Krause J
JAMA; 2001 Sep; 286(11):1331-9. PubMed ID: 11560538
[TBL] [Abstract][Full Text] [Related]
10. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity.
Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
Int J Obes Relat Metab Disord; 2000 Feb; 24(2):144-50. PubMed ID: 10702763
[TBL] [Abstract][Full Text] [Related]
11. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
Fujioka K; Seaton TB; Rowe E; Jelinek CA; Raskin P; Lebovitz HE; Weinstein SP;
Diabetes Obes Metab; 2000 Jun; 2(3):175-87. PubMed ID: 11220553
[TBL] [Abstract][Full Text] [Related]
12. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.
McMahon FG; Fujioka K; Singh BN; Mendel CM; Rowe E; Rolston K; Johnson F; Mooradian AD
Arch Intern Med; 2000 Jul; 160(14):2185-91. PubMed ID: 10904462
[TBL] [Abstract][Full Text] [Related]
14. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
Mathus-Vliegen EM;
Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
[TBL] [Abstract][Full Text] [Related]
15. [A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects].
Zhao Y; Wang X; Yan Z
Zhonghua Yu Fang Yi Xue Za Zhi; 2001 Sep; 35(5):329-32. PubMed ID: 11769634
[TBL] [Abstract][Full Text] [Related]
16. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
Cuellar GE; Ruiz AM; Monsalve MC; Berber A
Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study.
Halpern A; Leite CC; Herszkowicz N; Barbato A; Costa AP
Rev Hosp Clin Fac Med Sao Paulo; 2002; 57(3):98-102. PubMed ID: 12118266
[TBL] [Abstract][Full Text] [Related]
18. The effect of sibutramine on energy expenditure and body composition in obese adolescents.
Van Mil EG; Westerterp KR; Kester AD; Delemarre-van de Waal HA; Gerver WJ; Saris WH
J Clin Endocrinol Metab; 2007 Apr; 92(4):1409-14. PubMed ID: 17264187
[TBL] [Abstract][Full Text] [Related]
19. Weight loss in obese African American and Caucasian adolescents: secondary analysis of a randomized clinical trial of behavioral therapy plus sibutramine.
Budd GM; Hayman LL; Crump E; Pollydore C; Hawley KD; Cronquist JL; Berkowitz RI
J Cardiovasc Nurs; 2007; 22(4):288-96. PubMed ID: 17589281
[TBL] [Abstract][Full Text] [Related]
20. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
Smith IG; Goulder MA;
J Fam Pract; 2001 Jun; 50(6):505-12. PubMed ID: 11407998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
